Combination Treatment with Daclatasvir Produces Good Results in Patients with Genotype 4 Hepatitis C

With limited and unsatisfactory treatment options currently available for patients with genotype 4 hepatitis C virus (HCV), the results from the COMMAND-4 study presented at IDWeek 2014 offer some promise for these hard-to-treat patients.

In the study, 82 patients with genotype 4 HCV were treated with 60 mg once daily of the NS5A inhibitor daclatasvir in combination with peginterferon alfa 180 µg once weekly and weight-based ribavirin (1000-1200 mg/day) twice daily. In the study’s other arm, 42 patients received placebo plus peginterferon alfa and ribavirin.

Researchers evaluated the safety and efficacy of this combination in treatment-naïve patients with genotype 4 HCV, including patients with cirrhosis. The primary endpoint of the study was sustained virologic response at 12 weeks (SVR12).

 - See more at: http://www.hcplive.com/conferences/idweek/Combination-Treatment-with-Daclatasvir-Produces-Good-Results-in-Patients-with-Genotype-4-Hepatitis-C#sthash.wH70EOnK.dpuf

Labels: , , , ,